Skip to main content
Erschienen in: Acta Neuropathologica 4/2008

01.04.2008 | Original Paper

The progression of pathology in longitudinally followed patients with Parkinson’s disease

verfasst von: Glenda Halliday, Mariese Hely, Wayne Reid, John Morris

Erschienen in: Acta Neuropathologica | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

The present study describes the pathological progression of longitudinally followed cases with levodopa-responsive Parkinson’s disease who came to autopsy during the Sydney Multicenter Study of Parkinson’s disease. Standardised clinical and neuropathological assessments over five epochs of time verified three different clinicopathological groups. A group of younger onset patients with a typical long duration clinical course of Parkinson’s disease. This group of cases had Lewy body distributions consistent with the Braak staging of disease. In this group, brainstem Lewy bodies dominate in those surviving to 5 years; by 13 years, 50% of cases have a limbic distribution of Lewy bodies; and by 18 years, all will have at least this pathological phenotype. Approximately 25% of cases had an early malignant, dementia-dominant syndrome and severe neocortical disease consistent with dementia with Lewy bodies. The last group had an older onset, shorter survival, and a more complex disease course with higher Lewy body loads and a higher proportion with additional neuropathologies. These cases with higher loads of Lewy bodies and shorter survivals suggest that widespread Lewy body pathology either occurs at the onset of clinical disease or rapidly infiltrates the brain. In these cases with shorter survivals, there was more plaque pathology, supporting a more aggressive and linked phenotype. Our data suggest that the selection of similar study cohorts by pathology alone would not be able to differentiate the three different phenotypes identified. The data are also not consistent with a unitary concept of the pathogenesis of Lewy body disease.
Literatur
1.
Zurück zum Zitat Beyer MK, Larsen JP, Aarsland D (2007) Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 69:747–754PubMedCrossRef Beyer MK, Larsen JP, Aarsland D (2007) Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 69:747–754PubMedCrossRef
2.
Zurück zum Zitat Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef
3.
Zurück zum Zitat Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410PubMed Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410PubMed
4.
Zurück zum Zitat Braak H, Rub U, Del Tredici K (2006) Cognitive decline correlates with neuropathological stage in Parkinson’s disease. J Neurol Sci 248:255–258PubMedCrossRef Braak H, Rub U, Del Tredici K (2006) Cognitive decline correlates with neuropathological stage in Parkinson’s disease. J Neurol Sci 248:255–258PubMedCrossRef
5.
Zurück zum Zitat Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 123(Pt 4):733–745PubMedCrossRef Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 123(Pt 4):733–745PubMedCrossRef
6.
Zurück zum Zitat Galvin JE, Pollack J, Morris JC (2006) Clinical phenotype of Parkinson disease dementia. Neurology 67:1605–1611PubMedCrossRef Galvin JE, Pollack J, Morris JC (2006) Clinical phenotype of Parkinson disease dementia. Neurology 67:1605–1611PubMedCrossRef
7.
Zurück zum Zitat Halliday G, Ng T, Rodriguez M, Harding A, Blumbergs P, Evans W, Fabian V, Fryer J, Gonzales M, Harper C, Kalnins R, Masters CL, McLean C, Milder DG, Pamphlett R, Scott G, Tannenberg A, Kril J (2002) Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. Acta Neuropathol 104:72–78PubMedCrossRef Halliday G, Ng T, Rodriguez M, Harding A, Blumbergs P, Evans W, Fabian V, Fryer J, Gonzales M, Harper C, Kalnins R, Masters CL, McLean C, Milder DG, Pamphlett R, Scott G, Tannenberg A, Kril J (2002) Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. Acta Neuropathol 104:72–78PubMedCrossRef
8.
Zurück zum Zitat Harding AJ, Broe GA, Halliday GM (2002) Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125:391–403PubMedCrossRef Harding AJ, Broe GA, Halliday GM (2002) Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125:391–403PubMedCrossRef
9.
Zurück zum Zitat Hely MA, Morris JG, Rail D, Reid WG, O’Sullivan DJ, Williamson PM, Genge S, Broe GA (1989) The Sydney Multicentre Study of Parkinson’s disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry 52:324–328PubMedCrossRef Hely MA, Morris JG, Rail D, Reid WG, O’Sullivan DJ, Williamson PM, Genge S, Broe GA (1989) The Sydney Multicentre Study of Parkinson’s disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry 52:324–328PubMedCrossRef
10.
Zurück zum Zitat Hely MA, Morris JG, Reid WG, O’Sullivan DJ, Williamson PM, Rail D, Broe GA, Margrie S (1994) The Sydney Multicentre Study of Parkinson’s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa–carbidopa. J Neurol Neurosurg Psychiatry 57:903–910PubMed Hely MA, Morris JG, Reid WG, O’Sullivan DJ, Williamson PM, Rail D, Broe GA, Margrie S (1994) The Sydney Multicentre Study of Parkinson’s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa–carbidopa. J Neurol Neurosurg Psychiatry 57:903–910PubMed
11.
Zurück zum Zitat Hely MA, Morris JG, Traficante R, Reid WG, O’Sullivan DJ, Williamson PM (1999) The Sydney Multicentre Study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 67:300–307PubMed Hely MA, Morris JG, Traficante R, Reid WG, O’Sullivan DJ, Williamson PM (1999) The Sydney Multicentre Study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 67:300–307PubMed
12.
Zurück zum Zitat Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord 20:190–199PubMedCrossRef Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord 20:190–199PubMedCrossRef
13.
Zurück zum Zitat Hely MA, Morris JGL, Reid WGJ, Adena MA, Halliday GM (2008) Sydney Multicenter Study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord (in press) Hely MA, Morris JGL, Reid WGJ, Adena MA, Halliday GM (2008) Sydney Multicenter Study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord (in press)
14.
Zurück zum Zitat Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54:1916–1921PubMed Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54:1916–1921PubMed
15.
Zurück zum Zitat Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 109:329–339PubMedCrossRef Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 109:329–339PubMedCrossRef
16.
Zurück zum Zitat Jellinger KA, Wenning GK, Seppi K (2007) Predictors of survival in dementia with lewy bodies and Parkinson dementia. Neurodegener Dis 4:428–430PubMedCrossRef Jellinger KA, Wenning GK, Seppi K (2007) Predictors of survival in dementia with lewy bodies and Parkinson dementia. Neurodegener Dis 4:428–430PubMedCrossRef
17.
Zurück zum Zitat Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ (2007) Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study. Brain 130:2123–2128PubMedCrossRef Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ (2007) Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study. Brain 130:2123–2128PubMedCrossRef
18.
19.
Zurück zum Zitat Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA (2005) Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 76:343–348PubMedCrossRef Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA (2005) Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 76:343–348PubMedCrossRef
20.
Zurück zum Zitat McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRef McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRef
21.
Zurück zum Zitat Papapetropoulos S, Gonzalez J, Lieberman A, Villar JM, Mash DC (2005) Dementia in Parkinson’s disease: a post-mortem study in a population of brain donors. Int J Geriatr Psychiatry 20:418–422PubMedCrossRef Papapetropoulos S, Gonzalez J, Lieberman A, Villar JM, Mash DC (2005) Dementia in Parkinson’s disease: a post-mortem study in a population of brain donors. Int J Geriatr Psychiatry 20:418–422PubMedCrossRef
22.
Zurück zum Zitat Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91PubMedCrossRef Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91PubMedCrossRef
23.
Zurück zum Zitat Reid WGJ, Broe GA, Hely MA, Morris JGL, Williamson PM, O’Sullivan DJ, Rail D, Genge SA, Moss NG (1989) The neuropsychology of de novo patients with idiopathic Parkinson’s disease: the effects of age of onset. Int J Neurosci 48:205–217PubMedCrossRef Reid WGJ, Broe GA, Hely MA, Morris JGL, Williamson PM, O’Sullivan DJ, Rail D, Genge SA, Moss NG (1989) The neuropsychology of de novo patients with idiopathic Parkinson’s disease: the effects of age of onset. Int J Neurosci 48:205–217PubMedCrossRef
24.
Zurück zum Zitat Reid WGJ (1992) The evolution of dementia in idiopathic Parkinson’s disease: neuropsychological and clinical evidence in support of subtypes. Int Psychogeriatr 4(Suppl 2):147–160PubMed Reid WGJ (1992) The evolution of dementia in idiopathic Parkinson’s disease: neuropsychological and clinical evidence in support of subtypes. Int Psychogeriatr 4(Suppl 2):147–160PubMed
25.
Zurück zum Zitat Reid WGJ, Hely MA, Morris JGL, Broe GA, Adena M, O’Sullivan DJ, Williamson PM (1996) A longitudinal study of Parkinson’s disease: clinical and neuropsychological correlates of dementia. J Clin Neurosci 3:327–333CrossRefPubMed Reid WGJ, Hely MA, Morris JGL, Broe GA, Adena M, O’Sullivan DJ, Williamson PM (1996) A longitudinal study of Parkinson’s disease: clinical and neuropsychological correlates of dementia. J Clin Neurosci 3:327–333CrossRefPubMed
26.
Zurück zum Zitat The National Institute on Aging, Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. Neurobiol Aging 18: S1–S2CrossRef The National Institute on Aging, Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. Neurobiol Aging 18: S1–S2CrossRef
27.
Zurück zum Zitat Williams DR, Lees AJ (2005) Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol 4:605–610PubMedCrossRef Williams DR, Lees AJ (2005) Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol 4:605–610PubMedCrossRef
Metadaten
Titel
The progression of pathology in longitudinally followed patients with Parkinson’s disease
verfasst von
Glenda Halliday
Mariese Hely
Wayne Reid
John Morris
Publikationsdatum
01.04.2008
Verlag
Springer-Verlag
Erschienen in
Acta Neuropathologica / Ausgabe 4/2008
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-008-0344-8

Weitere Artikel der Ausgabe 4/2008

Acta Neuropathologica 4/2008 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.